Reuters logo
BRIEF-Cytokinetics Inc announces negative results from VITALITY-ALS
November 21, 2017 / 12:42 PM / 22 days ago

BRIEF-Cytokinetics Inc announces negative results from VITALITY-ALS

Nov 21 (Reuters) - Cytokinetics Inc

* Cytokinetics announces negative results from VITALITY-ALS

* Phase 3 clinical trial of Tirasemtiv in patients with ALS did not meet primary or secondary endpoints​

* No new safety or tolerability findings related to Tirasemtiv were identified in VITALITY-ALS​

* Believe that limitations of Tirasemtiv may be addressed with co’s next-generation fast skeletal muscle activator, CK-2127107​

* Have decided to suspend development of Tirasemtiv​

* Limitations of Tirasemtiv may be addressed with co’s “next-generation fast” skeletal muscle activator, CK-2127107​

* Believe CK-2127107 will be better tolerated, potentially more effective than Tirasemtiv for ALS & look forward to phase 2 results in 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below